• $7.2 million Q3 Revenue - 352% increase on Q3 FY2024
• $8.5 million Q3 Cash Receipts - 14% increase on prior quarter and 238% increase on Q3 FY2024
• On track to exceed FY2025 revenue forecast of $25 million

Bioxyne Ltd (ASX:BXN), an Australian life sciences, pharmaceutical and consumer health products company, has reported a strong Q3 FY2025 trading performance. The company achieved $7.2 million in revenue, a 352% increase on Q3 FY2024, and $8.5 million in cash receipts, a 14% increase on the prior quarter and a 238% increase on Q3 FY2024. Year to date revenue is $19.7 million, up 213% on the prior year. The company is on track to exceed its FY2025 revenue forecast of $25 million. Bioxyne generated positive cash flow of $1.9 million in Q3, after investing in working capital, plant and machinery to support the significant growth of the business. The company's wholly-owned subsidiary, Breathe Life Sciences (BLS), is the major contributor to the group's results, as Australia's leading manufacturer and wholesaler of novel medicines, including cannabis, MDMA, and Psilocybin. Bioxyne also plans further investment in the rapidly growing markets of the UK and Europe.

The company reaffirms its guidance of $25 million in revenue for FY2025 and will continue to assess increasing guidance as it gains visibility on order volumes throughout Q4 FY2025.

The company is focused on growing its manufacturing customer base in Australia, the UK, and Europe, exceeding its revenue forecast of $25 million for FY2025, gaining EU GMP certification in Czechia for distribution to European markets, and launching its medicinal cannabis products in the UK and European markets with local partners.